Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + regorafenib + camrelizumab for second-line hepatocellular carcinoma after prior TKI
ChiCTR2100045144Phase 2Recruiting
- Sponsor
- Army Medical University
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by Army Medical University. Primary endpoint: Disease remission rate. Started Apr 2021; status: recruiting.
02
Drugs
regorafenibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100045144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045144.